U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C4H5NO4.C2H4NO2.Fe.H
Molecular Weight 261.998
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS ASPARTO GLYCINATE

SMILES

[H+].[Fe++].NCC([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O

InChI

InChIKey=SITDSFUWDSKJII-JIZZDEOASA-L
InChI=1S/C4H7NO4.C2H5NO2.Fe/c5-2(4(8)9)1-3(6)7;3-1-2(4)5;/h2H,1,5H2,(H,6,7)(H,8,9);1,3H2,(H,4,5);/q;;+2/p-2/t2-;;/m0../s1

HIDE SMILES / InChI
Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
PubMed

PubMed

TitleDatePubMed
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS.
1932 Nov 11
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A.
1932 Sep 30
[FERROUS ASPARTATE IN THERAPY].
1964 Jan 1
[Historical notes on the therapy of depression].
1986 Nov 22
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.
2011 Jun 10
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example.
2017 Jul 5
Patents

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
FERROUS ASPARTO GLYCINATE
WHO-DD  
Common Name English
Ferrous asparto glycinate [WHO-DD]
Common Name English
Code System Code Type Description
DRUG BANK
DB11169
Created by admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
PRIMARY
PUBCHEM
73415801
Created by admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
PRIMARY
RXCUI
644718
Created by admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
PRIMARY RxNorm
FDA UNII
H7426RGB3L
Created by admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
PRIMARY
EVMPD
SUB130739
Created by admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
PRIMARY
DAILYMED
H7426RGB3L
Created by admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
PRIMARY
SMS_ID
100000156746
Created by admin on Fri Dec 15 16:01:25 GMT 2023 , Edited by admin on Fri Dec 15 16:01:25 GMT 2023
PRIMARY